TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05302284: A Open-Label, Multicenter, Randomised, Controlled Phase 3 Study of RC48-ADC Plus Toripalimab Versus Chemotherapy Alone in Previously Untreated Unresectable Locally Advanced or Metastatic Urothelial Carcinoma With HER2-Ex

Sponsor: RemeGen Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 452 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT05302284 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05302284 Rescue Dossier →